EMEA-002016-PIP02-16

Key facts

Active substance
Alpelisib
Therapeutic area
Oncology
Decision number
P/0079/2017
PIP number
EMEA-002016-PIP02-16
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of breast cancer
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Ltd
Switzerland
E-mail: paediatric.enquiries@novartis.com
Tel.: +41 (0)613241111
Fax: +41 (0)613248001
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating